Edition:
United Kingdom

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

9.27CAD
7:13pm BST
Change (% chg)

$0.02 (+0.22%)
Prev Close
$9.25
Open
$9.25
Day's High
$9.31
Day's Low
$9.20
Volume
51,233
Avg. Vol
142,875
52-wk High
$10.05
52-wk Low
$4.96

Latest Key Developments (Source: Significant Developments)

Theratechnologies Reports Q4 Loss Per Share Of C$0.06
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2017.Q4 REVENUE C$12.6 MILLION VERSUS C$10.38 MILLION.Q4 LOSS PER SHARE C$0.06.  Full Article

Theratechnologies Q3 loss per share c$0.04
Thursday, 5 Oct 2017 

Oct 5 (Reuters) - Theratechnologies Inc ::Theratechnologies announces financial results for third quarter of 2017.Q3 loss per share c$0.04.Q3 earnings per share view c$-0.03 -- Thomson Reuters I/B/E/S.Theratechnologies - ‍net sales revenue of Egrifta for fiscal 2017 is now expected to be in range of $42 million to $44 million​.  Full Article

Theratechnologies reports Q2 loss per share C$0.13
Wednesday, 12 Jul 2017 

July 12 (Reuters) - Theratechnologies Inc -:Theratechnologies announces financial results for second quarter of 2017.Q2 loss per share c$0.13.Q2 earnings per share view c$-0.03 -- Thomson Reuters I/B/E/S.Theratechnologies Inc - ‍no change in our previously reported guidance for 2017​.Theratechnologies Inc - ‍consolidated revenue for three-month ended May 31, 2017 was $10.016 million compared to $9.027 million.  Full Article

Theratechnologies says FDA sets PDUFA date of Jan 3 for ibalizumab application
Friday, 30 Jun 2017 

June 30 (Reuters) - Theratechnologies Inc ::FDA grants priority review to HIV monoclonal antibody and long-acting investigational antiretroviral ibalizumab.FDA has set a prescription drug user fee act target action date of January 3, 2018, for ibalizumab application.  Full Article

Theratechnologies Q1 loss per share C$0.03
Thursday, 6 Apr 2017 

Theratechnologies Inc : Theratechnologies announces financial results for first quarter of 2017 . Q1 sales c$9.034 million . Q1 loss per share c$0.03 .Theratechnologies Inc - net sales revenue of Egrifta(®) for fy 17 is now expected to be in range of $44 million to $46 million (previously $40 million to $42 million).  Full Article

Theratechnologies Q1 loss per share C$0.03
Thursday, 6 Apr 2017 

Theratechnologies Inc : Theratechnologies announces financial results for first quarter of 2017 . Q1 sales C$9.034 million .Q1 loss per share C$0.03.  Full Article

Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories
Monday, 6 Mar 2017 

Theratechnologies Inc : Theratechnologies inc - agreement also includes upfront payment of US$3m payable through issuance of 906,077 common shares of Theratechnologies . Theratechnologies acquires commercial rights to Ibalizumab in the european union and four additional territories . Theratechnologies-Existing agreement between both companies has been amended to include additional territories and related new obligations . Theratechnologies inc -reached agreement with Taimed Biologics,for acquisition of commercial rights to Ibalizumab in European Union, Israel, Norway, Russia and Switzerland . Says under terms of agreement, Theratechnologies will assume regulatory responsibilities and associated costs . Theratechnologies inc - both parties have agreed to a transfer price of 52% for annual European sales up to us$50m .Says transfer price will increase to 57% on annual sales above us$50m threshold.  Full Article

Theratechnologies posts Q4 earnings per share C$0.00
Wednesday, 8 Feb 2017 

Theratechnologies Inc : Theratechnologies announces financial results for fiscal year 2016 . Q4 revenue C$10.38 million versus I/B/E/S view c$9.6 million . Q4 earnings per share C$0.00 . Theratechnologies Inc - anticipate that FY net sales revenue will be in range of $40 million to $42 million .Theratechnologies -"we are now finalizing our plans for launch of ibalizumab in United States, which we believe will occur in 2017, if approved".  Full Article

Theratechnologies announces $16.5 mln bought deal financing
Monday, 14 Nov 2016 

Theratechnologies Inc : Theratechnologies announces $16.5 million bought deal financing .Underwriters to purchase, on a bought-deal basis, 5.3 million common shares of company at a price of $3.10 per common share.  Full Article

Theratechnologies Inc Q3 EPS C$0.01
Tuesday, 4 Oct 2016 

Theratechnologies Inc : Q3 earnings per share C$0.01 . Theratechnologies announces financial results for third quarter of 2016 . Q3 sales C$8.925 million .Theratechnologies Inc - Based upon results of our Q3, our guidance for year remains unchanged.  Full Article

BRIEF-Theratechnologies To Seek Regulatory Approval Of Trogarzo In Europe

* THERATECHNOLOGIES TO SEEK REGULATORY APPROVAL OF TROGARZO™ (IBALIZUMAB) IN EUROPE